The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
24
Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
Unnamed facility
Brighton, Massachusetts, United States
Area under the plasma concentration versus time curve from zero to infinity ( Plasma AUCinf) of BAY73-4506 given alone or with ketoconazole.
Time frame: 1 month
Peak plasma concentration (Cmax) of BAY73-4506 given alone or with ketoconazole
Time frame: 1 month
Plasma AUCinf of metabolites of a single oral dose BAY73-4506 given alone or with ketoconazole.
Time frame: 1 month
Plasma Cmax of metabolites of a single oral dose BAY73-4506 given alone or with ketoconazole.
Time frame: 1 month
Number of subjects with adverse events following a single oral dose of BAY73-4506, adminstered alone and concomitantly with ketoconazole.
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.